Clinical Trials
18 trialsNCT03367741 2026-05-19
Cabozantinib S-malate and Nivolumab in Treating Patients With Advanced, Recurrent, or Metastatic Endometrial Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT02834013 2026-05-13
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT03660826 2026-05-04
Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06638931 2026-04-15
ANTARES
Instituto do Cancer do Estado de São Paulo
Phase 2 Recruiting
NCT05500391 2026-03-18
SUR-CAN
Centre Oscar Lambret
Phase 2 Recruiting
NCT04065269 2026-02-20
ATARI
Institute of Cancer Research, United Kingdom
Phase 2 Active not recruiting
NCT03395080 2025-08-01
P204
Leap Therapeutics, Inc.
Phase 2 Completed
NCT04513665 2025-05-22
ZW25 in Women With Endometrial Cancers
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT03241745 2024-12-27
A Study of Nivolumab in Selected Uterine Cancer Patients
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT02203760 2024-11-15
PazoDoble
North Eastern German Society of Gynaecological Oncology
Phase 2 Active not recruiting
NCT04171700 2023-10-02
LODESTAR
pharmaand GmbH
Phase 2 Terminated
NCT05265793 2022-03-04
Camrelizumab Combined With Apatinib in the Treatment of Advanced Sarcomatoid Carcinoma or Carcinosarcoma
Fudan University
Phase 2 Unknown
NCT03570437 2022-03-02
COPELIA
University of Manchester
Phase 2 Unknown
NCT05224999 2022-02-04
Nivolumab for Recurrent/Metastatic Carcinosarcoma
Yonsei University
Phase 2 Unknown
NCT02993705 2021-08-25
MITO 26
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase 2 Completed
NCT03933761 2021-08-10
PRECISE
Australia New Zealand Gynaecological Oncology Group
Phase 2 Withdrawn
NCT00815945 2017-02-14
Multicenter Trial With PegLiposomal Doxorubicin and Carboplatin Combination Chemotherapy in Gynecological Sarcomas and Mixed Epithelial-Mesenchymal Tumors
AGO Study Group
Phase 2 Completed
NCT00505492 2011-09-15
Malignant Mixed Mesodermal Tumor (MMMT) - Early Stage With Postoperative XRT/Chemotherapy
M.D. Anderson Cancer Center
Phase 2 Terminated